Latest Non-Hodgkin lymphoma Stories
Hodgkin's lymphoma is one of the most treatable cancers, with more than 90 percent of patients surviving after a combination of radiation and chemotherapy.
Researchers at the University of Maryland School of Medicine have discovered a novel interaction between two proteins involved in regulating cell growth that could provide possible new drug targets for treating diffuse large B-cell lymphoma, the most common type of non-Hodgkin's lymphoma.
Researchers from the University of Sheffield have discovered valuable insight into how people develop B-cell lymphoma, one of the most common cancers in the UK.
Researchers at North Carolina State University are narrowing the search for genes involved in non-Hodgkin lymphoma â€“ by turning dogs into humans.
SAN DIEGO, Feb. 16, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc.
ORLANDO, Fla. and SUNNYVALE, Calif., Dec. 7, 2010 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc.
SEATTLE, Nov. 18, 2010 /PRNewswire/ -- Cell Therapeutics, Inc.
Long-term use of statins is unlikely to substantially increase or decrease overall cancer risk, but was associated with lowering risk of melanoma, endometrial cancer and non-Hodgkin lymphoma.
Diffuse large B-cell lymphoma (DLBCL) is a type of aggressive non-Hodgkin's lymphoma that accounts for approximately 40 percent of lymphomas among adults.
Diffuse large B cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma.
- a slit in a tire to drain away surface water and improve traction.